TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Care Unit(ICU)-Acquired Paresis and the Risk for Mortality and Recurrent ICU Admission (Weakness and ICU Readmission Evaluation-WIRE)
Brief Summary: This study seeks to define the morbidity of critical care polyneuropathy and to confirm that this diagnosis is, in fact, independently associated with increased mortality. Secondary information regarding the reasons for ICU readmission in patients with weakness may help in formulating cogent discharge strategies for these patients. Measurement of weakness using handgrip strength may provide a useful surrogate marker for weakness that may be more easily and uniformly applied.

Primary hypothesis:

* The development of ICU-associated weakness is independently associated with excess attributable mortality.

Secondary hypothesis:

* The development of ICU-associated weakness is associated with an increased need for ICU readmission.
* Readmission to the ICU will be a result of the development of recurrent respiratory failure or insufficiency
* Handgrip strength testing will detect ICU-associated weakness with an equivalent sensitivity as the comprehensive bedside muscle strength exam.


Options:
A: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
B: Arm Label: Intensive physical therapy; Type: EXPERIMENTAL; Interventions: Procedure: intensive physical therapy | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: control group | Intervention Type: PROCEDURE; Name: intensive physical therapy; Assigned to Arm(s): Intensive physical therapy | Intervention Type: PROCEDURE; Name: control group; Assigned to Arm(s): control group
C: N/A
D: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Care Unit(ICU)-Acquired Paresis and the Risk for Mortality and Recurrent ICU Admission (Weakness and ICU Readmission Evaluation-WIRE)
Brief Summary: This study seeks to define the morbidity of critical care polyneuropathy and to confirm that this diagnosis is, in fact, independently associated with increased mortality. Secondary information regarding the reasons for ICU readmission in patients with weakness may help in formulating cogent discharge strategies for these patients. Measurement of weakness using handgrip strength may provide a useful surrogate marker for weakness that may be more easily and uniformly applied.

Primary hypothesis:

* The development of ICU-associated weakness is independently associated with excess attributable mortality.

Secondary hypothesis:

* The development of ICU-associated weakness is associated with an increased need for ICU readmission.
* Readmission to the ICU will be a result of the development of recurrent respiratory failure or insufficiency
* Handgrip strength testing will detect ICU-associated weakness with an equivalent sensitivity as the comprehensive bedside muscle strength exam.


Options:
A: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
B: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Resistance training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Resistance training; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2
D: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
Brief Summary: The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: folic acid, vitamin B12 (cyanocobalamin) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin B6 (pyridoxine) | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: folic acid, vitamin B12 (cyanocobalamin); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: vitamin B6 (pyridoxine); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
B: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
Brief Summary: The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus.


Options:
A: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
Brief Summary: The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4
D: Arm Label: gentamicin Group; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge dipped in saline | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: gentamicin-collagen sponge dipped in saline; Assigned to Arm(s): gentamicin Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
Brief Summary: The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benfotiamine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benfotiamine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Niacinamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niacinamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
Brief Summary: The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alzheimer's Disease Neuroimaging Initiative
Brief Summary: The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Stimulation | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Stimulation; Assigned to Arm(s): Intervention Group
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Individual Cognitive Stimulation Therapy; Type: EXPERIMENTAL; Interventions: Other: Individual Cognitive Stimulation Therapy Program | Intervention Type: OTHER; Name: Individual Cognitive Stimulation Therapy Program; Assigned to Arm(s): Individual Cognitive Stimulation Therapy
C: Arm Label: 1; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 2; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 3; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging (MRI); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Positron Emission Tomography (PET); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Lumbar Puncture (LP); Assigned to Arm(s): 1, 2, 3
D: Arm Label: iCST web-application; Type: EXPERIMENTAL; Interventions: Behavioral: iCST web-application | Arm Label: Treatment as usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: iCST web-application; Assigned to Arm(s): iCST web-application

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alzheimer's Disease Neuroimaging Initiative
Brief Summary: The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Intervention Type: BEHAVIORAL; Name: Nutritional programme; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 2; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 3; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging (MRI); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Positron Emission Tomography (PET); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Lumbar Puncture (LP); Assigned to Arm(s): 1, 2, 3
D: Intervention Type: DRUG; Name: EPAX 1050TG; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alzheimer's Disease Neuroimaging Initiative
Brief Summary: The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.


Options:
A: Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2
D: Arm Label: 1; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 2; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 3; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging (MRI); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Positron Emission Tomography (PET); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Lumbar Puncture (LP); Assigned to Arm(s): 1, 2, 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)
Brief Summary: The study is being conducted to demonstrate the non-inferiority of carotid artery stenting (CAS) using the Emboshield® Embolic Protection System with the Xact® Carotid Stent System to carotid endarterectomy (CEA) for the treatment of asymptomatic extracranial carotid atherosclerotic disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid artery stenting with filter (interventional) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid artery endarterectomy (surgical) | Intervention Type: DEVICE; Name: Carotid artery stenting with filter (interventional); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Carotid artery endarterectomy (surgical); Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Cordis Nitinol Stent; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: PRECISE tapered stent; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ANGIOGUARD XP Emboli Capture Guidewire (ECGW); Assigned to Arm(s): N/A
C: N/A
D: Arm Label: MICHI NPS+f; Type: EXPERIMENTAL; Interventions: Device: MICHI NPS+f | Intervention Type: DEVICE; Name: MICHI NPS+f; Assigned to Arm(s): MICHI NPS+f

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)
Brief Summary: The study is being conducted to demonstrate the non-inferiority of carotid artery stenting (CAS) using the Emboshield® Embolic Protection System with the Xact® Carotid Stent System to carotid endarterectomy (CEA) for the treatment of asymptomatic extracranial carotid atherosclerotic disease.


Options:
A: Arm Label: MICHI NPS+f; Type: EXPERIMENTAL; Interventions: Device: MICHI NPS+f | Intervention Type: DEVICE; Name: MICHI NPS+f; Assigned to Arm(s): MICHI NPS+f
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid artery stenting with filter (interventional) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid artery endarterectomy (surgical) | Intervention Type: DEVICE; Name: Carotid artery stenting with filter (interventional); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Carotid artery endarterectomy (surgical); Assigned to Arm(s): 2
C: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS
D: Arm Label: Closed-cell stent (Xact stent); Type: ACTIVE_COMPARATOR; Interventions: Device: closed-cell stent (Xact stent) | Arm Label: Open-cell stent (Acculink carotid); Type: ACTIVE_COMPARATOR; Interventions: Device: Open-cell stent (Acculink carotid) | Intervention Type: DEVICE; Name: closed-cell stent (Xact stent); Assigned to Arm(s): Closed-cell stent (Xact stent) | Intervention Type: DEVICE; Name: Open-cell stent (Acculink carotid); Assigned to Arm(s): Open-cell stent (Acculink carotid)

Answer: B